<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525886</url>
  </required_header>
  <id_info>
    <org_study_id>NBI-74788-CAH2001</org_study_id>
    <nct_id>NCT03525886</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia</brief_title>
  <official_title>A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adult Subjects With Congenital Adrenal Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurocrine Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurocrine Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, multiple-dose, dose-escalation study to assess the safety,&#xD;
      tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 in up to 30 adult&#xD;
      female and male subjects (18 to 50 years of age) with a documented medical diagnosis of&#xD;
      classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). The study will&#xD;
      include a sequential-cohort design with three NBI-74788 dose cohorts, with each dose&#xD;
      administered for 14 consecutive days. Cohort 3 will be conducted in parallel with cohort 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Actual">April 7, 2020</completion_date>
  <primary_completion_date type="Actual">April 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events following dosing of NBI-74788</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of NBI-74788 and its metabolites following dosing of NBI-74788</measure>
    <time_frame>From baseline up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of 17-hydroxyprogesterone (17-OHP) following dosing of NBI-74788</measure>
    <time_frame>From baseline up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of biomarkers following dosing of NBI-74788</measure>
    <time_frame>From baseline up to 7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>CAH - Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>NBI-74788 Dose Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NBI-74788 administered orally for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBI-74788 Dose Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NBI-74788 administered orally for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 2 will be dosed in parallel with Group 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBI-74788 Dose Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 3 will be dosed in parallel with Group 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBI-74788 Dose Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NBI-74788</intervention_name>
    <description>Capsule, administered daily.</description>
    <arm_group_label>NBI-74788 Dose Group 1</arm_group_label>
    <arm_group_label>NBI-74788 Dose Group 2</arm_group_label>
    <arm_group_label>NBI-74788 Dose Group 3</arm_group_label>
    <arm_group_label>NBI-74788 Dose Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be in good general health.&#xD;
&#xD;
          2. Have a medically confirmed diagnosis of classic 21-hydroxylase deficiency CAH.&#xD;
&#xD;
          3. Be on a stable regimen of steroidal treatment for CAH that is expected to remain&#xD;
             stable throughout the study.&#xD;
&#xD;
          4. Subjects of childbearing potential must be instructed on the proper use of barrier&#xD;
             methods of contraception and agree to use hormonal or two forms of nonhormonal&#xD;
             contraception (dual contraception) consistently from screening until the final study&#xD;
             visit or a prespecified window after the last dose of study drug, whichever is longer.&#xD;
&#xD;
          5. Subjects of childbearing potential must have a negative pregnancy test at screening&#xD;
             and negative urine pregnancy test at baseline.&#xD;
&#xD;
          6. Have a negative urine drug (for illegal drugs) and alcohol breath test at screening&#xD;
             and baseline.&#xD;
&#xD;
          7. Be willing and able to adhere to the study regimen and study procedures described in&#xD;
             the protocol and informed consent/assent form, including all requirements at the study&#xD;
             center and return for the follow-up visit.&#xD;
&#xD;
          8. Be willing to provide authorization for access to personal health information in&#xD;
             conjunction with US Health Insurance Portability and Accountability Act (HIPAA).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a clinically significant unstable medical condition or chronic disease, or&#xD;
             malignancy.&#xD;
&#xD;
          2. Had a medically significant illness within 30 days of screening.&#xD;
&#xD;
          3. Have a known or suspected differential diagnosis of any of the other known forms of&#xD;
             classic CAH.&#xD;
&#xD;
          4. Have a history that includes bilateral adrenalectomy, hypopituitarism, or other&#xD;
             condition requiring daily therapy with orally administered glucocorticoids.&#xD;
&#xD;
          5. Are pregnant or lactating females.&#xD;
&#xD;
          6. Have a history of epilepsy or serious head injury.&#xD;
&#xD;
          7. Have a known history of long QT syndrome or cardiac tachy-arrhythmia.&#xD;
&#xD;
          8. Have hypersensitivity to any corticotropin releasing hormone antagonists.&#xD;
&#xD;
          9. Test positive at screening for hepatitis B, hepatitis C, or human immunodeficiency&#xD;
             virus (HIV), or have a history of a positive result.&#xD;
&#xD;
         10. Have a recent history (≤1 year) of alcohol or drug abuse, or current evidence of&#xD;
             substance dependence or abuse criteria.&#xD;
&#xD;
         11. Used any anticoagulants or antiplatelet therapies within 30 days before screening.&#xD;
&#xD;
         12. Have an active bleeding disorder.&#xD;
&#xD;
         13. Used any other investigational drug within 30 days before initial screening, or plans&#xD;
             to use an investigational drug (other than the study drug) during the study.&#xD;
&#xD;
         14. Have a blood loss ≥550 mL or donated blood within 56 days or donated plasma within 7&#xD;
             days before baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurocrine Clinical Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cahlibratestudy.com</url>
    <description>Study website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

